Drug eluting implants to prevent cardiac apoptosis

• US 20050267556A1
• Filed: 05/28/2004
• Published: 12/01/2005
• Est. Priority Date: 05/28/2004
• Status: Abandoned Application

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Scheiner, Avram, Shuros, Allan, Salo, Rodney
• Application Number:
  US10/856,201
• Publication Number:
  US 20050267556A1
• Time in Patent Office: Days
• US Class Current: 607/120
• CPC Class Codes: A61L 2300/40 characterised by a specific therapeutic activity or mode of action
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: D04C 1/06 Braid or lace serving particular purposes
• CPC Class Codes: D10B 2509/00 Medical; Hygiene

Abstract

Implantable devices are configured to be positioned in or near the heart and to carry and deliver an anti-apoptotic drug to a treatment site in or near the heart. The implantable devices include, but are not limited to, leads, stents, heart valves, atrial septal defect devices, cardiac patches and ventricular restraint devices. Depending on the composition of the device, the drug may be carried by the device through a coating applied to the device, or may be included in the device during the device manufacturing process. The drug may also be included in microparticles, such a microspheres, that are delivered locally through a conduit, such as a catheter.

Claims

1. An implantable device configured to be positioned in or near the heart and to carry and deliver an anti-apoptotic drug to a treatment site.

2. The device of claim 1 wherein the anti-apoptotic drug comprises at least one of Caspase inhibitors, Map Kinase inhibitors, AIF inhibitors, TNF-α

receptor blocker and Phosphodiesterase inhibitor.

3. The device of claim 1 wherein the anti-apoptotic drug is configured to prevent the release of Cytochrome C.

4. The device of claim 1 wherein the anti-apoptotic drug further comprises at least one of β

adrenergic receptor blockers, ACE inhibitors, anti-inflammatory drugs and Angiotensin II receptor blockers.

5. The device of claim 1 wherein the implantable device comprises a lead and the anti-apoptotic drug is included in a coating applied to the lead.

6. The device of claim 1 wherein the implantable device comprises a lead and the drug is included in a drug eluting matrix carried by the lead.

7. The device of claim 6 wherein the drug eluting matrix is configured to elute the drug upon contact with fluid

8. The device of claim 6 wherein the drug eluting matrix is at least partially positioned to be subjected to an electric field and is configured to elute the drug when subjected to the electric field.

9. The device of claim 1 wherein the implantable device comprises a lead and the anti-apoptotic drug is included in a silicone based component secured to the lead.

10. The device of claim 1 wherein the implantable device comprises a lead and the anti-apoptotic drug is included in an osmotic pump carried by the lead.

11. The device of claim 1 wherein the implantable device comprises a lead and the anti-apoptotic drug is included in a controllable pump carried by the lead.

12. The device of claim 1 wherein the implantable device comprises a stent and the anti-apoptotic drug is included in a coating applied to the stent.

13. The device of claim 1 wherein the implantable device comprises a heart valve and the anti-apoptotic drug is included in a coating applied to a component of the valve.

14. The device of claim 1 wherein the implantable device comprises a heart valve and the anti-apoptotic drug is included in a component of the valve.

15. The device of claim 1 wherein the implantable device comprises an anterior septal defect device or a patent foramen ovale device and the anti-apoptotic drug is included in a coating applied to a component of the device.

16. The device of claim 1 wherein the implantable device comprises a cardiac patch and the anti-apoptotic drug is included in a coating applied to a component of the patch.

17. The device of claim 1 wherein the implantable device comprises a cardiac patch and the anti-apoptotic drug is included in a component of the patch.

18. The device of claim 1 wherein the implantable device comprises a ventricular restraint device and the anti-apoptotic drug is included in a coating applied to a component of the device.

19. The device of claim 1 wherein the implantable device comprises a ventricular restraint device and the anti-apoptotic drug is included in a component of the device.

20. A system for providing local delivery of an anti-apoptotic drug to a local delivery area, said device comprising:

an implantable drug delivery conduit adapted to be positioned at or near the local delivery area;

a reservoir of microparticles carrying an anti-apoptotic drug, the reservoir in fluid communication with the drug delivery conduit; and

a pump for transferring the microparticles from the reservoir into the conduit for delivery at the local delivery area.

21. The system of claim 20 wherein the microparticles comprise microspheres.

22. A method of treating an ischemic or infarcted region of a heart comprising:

medicating an implantable device with an anti-apoptotic drug; and

positioning the implantable device at or near the infarcted region.

23. The method of claim 22 wherein medicating comprises applying a coating carrying the drug to a component of the implantable device.

24. The method of claim 22 wherein medicating comprises manufacturing a component of the implantable device to include the drug.